← All Nurix Therapeutics, INC filings

Nurix Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
NRIX
Nurix Therapeutics, INC
DEF: Nurix Therapeutics Advances Key Programs, Strengthens Balance Sheet
Nurix Therapeutics reports significant progress in its oncology and inflammation & immunology pipelines, highlighted by pivotal trial advancements for bexobrutideg and a strengthened financial position.
NASDAQ
NRIX
Nurix Therapeutics, INC
DEFA14A: Nurix Therapeutics Files Definitive Proxy Statement
Nurix Therapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
NRIX
Nurix Therapeutics, INC
DEF: Nurix Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Highlights Progress and Future Goals
Nurix Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 19, 2025, highlighting the company's advancements in targeted protein degradation medicines and strategic goals for the upcoming year.
NASDAQ
NRIX
Nurix Therapeutics, INC
DEFA14A: Nurix Therapeutics Files Definitive Proxy Statement
Nurix Therapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
NRIX
Nurix Therapeutics, INC
DEF 14A: Nurix Therapeutics Sets Date for 2024 Annual Stockholders Meeting
Nurix Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 20, 2024, to vote on director elections, ratification of the accounting firm, and executive compensation.